Ehrenkranz Partners L.P.
- SEC CIK
- 0001641043
- Latest filing
- Aug 14, 2026
The latest 13F from Ehrenkranz Partners L.P. covers Q2 2026 (filed Aug 14, 2026): 49 long positions worth $173.2M. The top 10 holdings make up 85.7% of the portfolio, and the largest is iShares Inc at 25.9%. Livermore has 4 filings on Form 13F from this institution, going back to Q3 2025.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 7
- Est. +$3.60M
- Added
- 14
- Est. +$28.0M
- Reduced
- 13
- Est. −$579.6K
- Sold out
- 5
- Est. −$11.6M
Top 5 holdings
Share of this quarter's portfolio value
- iShares Inc46428677225.9%$44.8M
- iShares Inc46434G82223.6%$40.9M
- SPYSPDR S&P 500 ETF Trust
- iShares MSCI Eafe ETF4642874656.6%$11.5M
- Invesco Exchange Traded FD T46137V3574.4%$7.61M
Share of portfolio
Top 5 holdings and the other 44 positions, by share of portfolio value
- iShares Inc25.9%
- iShares Inc23.6%
- SPY8.9%
- iShares MSCI Eafe ETF6.6%
- Invesco Exchange Traded FD T4.4%
- Other 44 positions30.6%
Biggest buys
New and added positions, by estimated amount bought
- iShares Inc46434G822+$13.0MAdded
- iShares MSCI Eafe ETF464287465+$8.47MAdded
- SPYSPDR S&P 500 ETF Trust
- Vanguard Morningstar Value ETF922908744+$2.48MAdded
- iShares Tr464288760+$2.21MNew
Largest weight increases
New and added positions, by percentage points of the portfolio gained
- iShares MSCI Eafe ETF464287465+4.40 pp2.2% → 6.6%
- iShares Inc46434G822+3.63 pp20.0% → 23.6%
- iShares Tr464288760+1.27 pp0.0% → 1.3%
- Vanguard Morningstar Value ETF922908744+1.05 pp2.0% → 3.1%
- SPYSPDR S&P 500 ETF Trust
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
- iShares MSCI USA Quality Factor ETF46432F339−4.17 pp4.2% → 0.0%
- Profesionally Managed Portfo74316P579−3.49 pp3.5% → 0.0%
- State Street SPDR S&P Biotech ETF78464A870−1.19 pp1.2% → 0.0%
- Vanguard Morningstar Mid-Cap ETF922908629−0.83 pp4.3% → 3.5%
- Vanguard S&P 500 ETF922908363−0.80 pp4.9% → 4.1%
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $173.2M
- +$46.8M (+37.0%) vs. prior quarter
- Positions
- 49
- +2 vs. prior quarter
- Top 10 concentration
- 85.7%
- Top 10 as share of value
- Turnover
- 8.1%
- Q2 2026, one quarter
- Average holding period
- 3.4 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q3 2025), so positions held before then are understated.
13F filings by quarter
4 quarters, going back to Q3 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $173.2M (Q2 2026)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 49 | $173.2M | iShares InciShares IncSPY | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 47 | $126.4M | iShares InciShares IncSPY | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 47 | $88.3M | iShares IncSPYVanguard S&P 500 ETF | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 32 | $114.1M | 2023 ETF Series TrustState Street SPDR S&P Biotech ETFiShares Inc | – | SEC |